Knowledge Discovery in Clinical Performance of Cancer Patients

2008 ◽  
Author(s):  
John Hayward ◽  
Sergio Alvarez ◽  
Carolina Ruiz ◽  
Mary Sullivan ◽  
Jennifer Tseng ◽  
...  
Keyword(s):  
Knowledge Discovery ◽  
Cancer Patients ◽  
Clinical Performance

Two-year clinical performance of glass ionomer and resin composite restorations in xerostomic head- and neck-irradiated cancer patients

2009 ◽  
Vol 15 (1) ◽  
pp. 31-38 ◽  
Author(s):  
Roeland J. G. De Moor ◽  
Inge G. Stassen ◽  
Yoke van ’t Veldt ◽  
Dries Torbeyns ◽  
Geert M. G. Hommez
Keyword(s):  
Head And Neck ◽  
Cancer Patients ◽  
Clinical Performance ◽  
Resin Composite ◽  
Glass Ionomer ◽  
Composite Restorations

scholarly journals Medical Liability in Cancer Care During COVID-19 Pandemic: Heroes or Guilty?

2020 ◽  
Vol 8 ◽  
Author(s):  
Rosario Barranco ◽  
Carlo Messina ◽  
Alessandro Bonsignore ◽  
Carlo Cattrini ◽  
Francesco Ventura
Keyword(s):  
Cancer Patients ◽  
Cancer Care ◽  
Clinical Decision Making ◽  
Clinical Performance ◽  
Performance Status ◽  
Clinical Decision ◽  
Hospital Environment ◽  
Tumor Board ◽  
Medical Liability ◽  
Careful Examination

Background: The COVID-19 outbreak rapidly became a public health emergency affecting particularly the frail category as cancer patients. This led oncologists to radical changes in patient management, facing the unprecedent issue whether treatments in oncology could be postponed without compromising their efficacy.Purpose: To discuss legal implications in oncology practice during the COVID-19 pandemic.Perspective: Treatment delay is not always feasible in oncology where the timing often plays a key role and may impact significantly in prognosis. During the COVID-19 pandemic, the oncologists were found between the anvil and the hammer, on the one hand the need to treat cancer patients aiming to improve clinical benefits, and on the other hand the goal to reduce the risk of COVID-19 infection avoiding or delaying immunosuppressive treatments and hospital exposure. Therefore, two rising scenarios with possible implications in both criminal and civil law are emerging. Firstly, oncologists may be “accused” of having delayed or omitted the diagnosis and/or treatments with consequent worsening of patients' outcome. Secondly, oncologists can be blamed for having exposed patients to hospital environment considered at risk for COVID-19 transmission.Conclusions: During the COVID-19 pandemic, clinical decision making should be well-balanced through a careful examination between clinical performance status, age, comorbidities, aim of the treatment, and the potential risk of COVID-19 infection in order to avoid the risk of suboptimal cancer care with potential legal repercussion. Moreover, all cases should be discussed in the oncology team or in the tumor board in order to share the best strategy to adopt case by case.

scholarly journals Scientific research with cancer patients during the COVID-19 pandemic: an experience report

2021 ◽  
Vol 2 (6) ◽  
Author(s):  
Milena Vieira Ramos
Keyword(s):  
Cancer Patients ◽  
Acoustic Analysis ◽  
Clinical Performance ◽  
Scientific Research ◽  
University Hospital ◽  
Outpatient Basis ◽  
Self Assessment ◽  
Medicine Research ◽  
Health Technologies

Scientific research brings resolutions to several problems in society, supporting clinical performance in health. Work with cancer patients needs to be even more careful. During the COVID-19 pandemic, cancer patients enter the risk group for exposure to the virus, limiting the monitoring of the disease, impairing treatment. New health technologies and telemedicine have been on the rise in recent years, changing the course of medicine, research and health care. Its implementation and validation have been widely discussed in recent years, and it was greatly encouraged by the COVID-19 pandemic. To report the development, adaptations and the six-month longitudinal follow-up of 20 individuals who underwent thyroidectomy at a university hospital. The research flowchart initially persisted in evaluating symptoms and vocal fatigue in individuals undergoing thyroidectomy due to thyroid cancer at three times: pre-surgical (M1), immediate post-surgical (M2) and late post-surgical (M3) in three to six months. The individuals were submitted to videolaryngoscopy, voice recording, voice acoustic analysis and completion of self-assessment protocols along with the medical consultation. All assessments were performed on an outpatient basis at the three times described. The research began in October 2019, and was interrupted at the beginning of the pandemic. In February 2020 we obtained eight cases with the two initial assessments, and only two cases with M3. Due to the pandemic, the surgeries were suspended and the continuity of the study was impaired, requiring modifications. The initial goal was to last nine months with 30 individuals in the sample. New cases were followed up from October 2020 until May 2021 when there was a reduction in cases. At the end, all data from 20 individuals in this period of the research were collected. The completion time increased from nine months to 20 months. None of the patients were infected by COVID-19 during the research period. Therefore, the treatment of cancer patients encompasses several aspects that have been hampered by its continuity, delaying deadlines and making access difficult by COVID-19. As well as, scientific research in this population has undergone several adaptations to preserve the health of individuals, not unnecessarily exposing them to contamination with the virus. Monitoring by telemedicine proved to be effective for the initial objectives of this study, but it may limit it depending on the type of proposed intervention. Despite the existing pandemic, scientific production should not be stopped because it brings discoveries that aim to improve the health of the population.

scholarly journals Clinical and technical evaluation of ACS™BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assays

1997 ◽  
Vol 43 (4) ◽  
pp. 585-593 ◽  
Author(s):  
Gijsbert G Bon ◽  
Silvia von Mensdorff-Pouilly ◽  
Peter Kenemans ◽  
Gerard J van Kamp ◽  
Rob A Verstraeten ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Performance ◽  
Linear Regression Analysis ◽  
Breast Disease ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Cancer Disease ◽  
Healthy Women ◽  
Technical Evaluation

Abstract The mucin glycoprotein-detecting assay CA 15-3 is a valuable tool for monitoring the course of disease in breast cancer patients. Assays of CA 15-3 are based on the use of two MAbs to polymorphic epithelial mucin (PEM). We evaluated the technical and clinical performance of the Chiron ACSTM BR, an automated competitive chemiluminescence assay using a single MAb, B27.29, and compared the assay’s results with those of the Centocor CA 15-3 RIA, the Abbott IMx CA 15-3, and the Boehringer Mannheim Enzymun-Test CA 15-3. The study population consisted of 253 healthy women, 66 patients with benign breast disease, 168 breast cancer patients, and 76 patients with other carcinomas. In the technical evaluation, we assessed the precision and linearity on dilution of the ACS BR assay. Cutoff values (upper limits of values seen in healthy subjects) were determined for all four assays. Agreement between the assays was studied by linear regression analysis. The ACS BR assay gave within- and between-assay CVs of 2.2% and 3.9%, respectively. Three samples from healthy women gave discordant values by ACS BR and were not included in the calculations. All four assays exhibit a highly similar pattern when monitoring breast cancer disease; the closest agreement of values was obtained between ACS BR and Centocor CA 15-3. We conclude that the ACS BR assay is a fast and reliable immunoassay for measuring PEM in serum. Although it detects a slightly different epitope on the PEM molecule than is targeted in other assays, for cancer serum samples it agreed better with the original Centocor CA 15-3 assay than did the other two CA 15-3 assays tested.

Multicenter Evaluation of the Performance and Clinical Utility in Longitudinal Monitoring of the Bayer Immuno 1™ Complexed PSA Assay

1999 ◽  
Vol 14 (2) ◽  
pp. 73-83 ◽  
Author(s):  
W. J. Allard ◽  
C. D. Cheli ◽  
D. L. Morris ◽  
J. Goldblatt ◽  
Y. Pierre ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Patients ◽  
Clinical Utility ◽  
Clinical Performance ◽  
Clinical Status ◽  
Clinical Effectiveness ◽  
Analytical Sensitivity ◽  
Course Of Disease ◽  
Clinical Sensitivity ◽  
Assay Performance

We conducted a multicenter evaluation of the analytical and clinical performance of the automated Bayer Immuno 1™ complexed PSA (cPSA) assay, and compared assay performance to the Bayer Immuno 1™ PSA assay. We sought to determine whether measurements of cPSA could be of clinical utility in the management of patients with prostate cancer. Results of the 10–day imprecision across three evaluation sites produced total CV < 2.50% and an analytical sensitivity of 0.02μg/L. There was an increased trend in clinical sensitivity for prostate cancer with increasing stage of disease (71–86%). Clinical specificity for patients with benign urogenital disease was 74.8%, and for other nonprostate diseases ranged from 91.1–100%. Retrospective serial monitoring of 155 patients with prostate cancer demonstrated concordance of cPSA measurements to clinical status for 97% of the patients analyzed. Results from the clinical studies using the Bayer Immuno 1 cPSA assay were comparable to results obtained with the Bayer Immuno 1 PSA assay. The Bayer Immuno 1 cPSA assay demonstrates analytical performance and clinical effectiveness in the management of prostate cancer patients during the course of disease and therapy.

scholarly journals Clinical Performance of (1,3) Beta-D Glucan for the Diagnosis of Pneumocystis Pneumonia (PCP) in Cancer Patients Tested With PCP Polymerase Chain Reaction

2018 ◽  
Vol 69 (8) ◽  
pp. 1303-1309 ◽  
Author(s):  
Sejal Morjaria ◽  
John Frame ◽  
Alexandra Franco-Garcia ◽  
Alexander Geyer ◽  
Mini Kamboj ◽  
...  
Keyword(s):  
Polymerase Chain Reaction ◽  
Cancer Patients ◽  
Predictive Value ◽  
Clinical Performance ◽  
Reference Method ◽  
Pneumocystis Pneumonia ◽  
Clinical Syndrome ◽  
Chain Reaction ◽  
Polymerase Chain ◽  
High Risk Cancer

Abstract Background Serum (1,3)-beta-D glucan (BDG) is increasingly used to guide the management of suspected Pneumocystis pneumonia (PCP). BDG lacks specificity for PCP, and its clinical performance in high-risk cancer patients has not been fully assessed. Polymerase chain reaction (PCR) for PCP detection is highly sensitive, but cannot differentiate between colonization and infection. We evaluated the diagnostic performance of serum BDG in conjunction with PCP PCR on respiratory samples in patients with cancer and unexplained lung infiltrates. Methods We performed a retrospective analysis of adult patients evaluated for PCP at our institution from 2012 to 2015, using serum BDG and PCP PCR. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the serum BDG at different thresholds were evaluated using PCP PCR alone or in conjunction with clinical presentation in PCP PCR–positive patients. Results With PCP PCR alone as the reference method, BDG (≥80 pg/mL) had a sensitivity of 69.8%, specificity of 81.2%, PPV of 34.6%, and NPV of 95.2% for PCP. At ≥200 pg/mL in patients with a positive PCR and a compatible PCP clinical syndrome, BDG had a sensitivity of 70%, specificity of 100%, PPV of 100%, and NPV of 52.0% for PCP. Conclusions Patients negative by both BDG and PCR were unlikely to have PCP. In patients with a compatible clinical syndrome for PCP, higher BDG values (>200 pg/mL) were consistently associated with clinically-significant PCP infections among PCP PCR–positive oncology patients.

scholarly journals Performance of the sōna Aspergillus Galactomannan Lateral Flow Assay in a Cancer Patient Population

2021 ◽  
Author(s):  
Krupa Jani ◽  
Tracy McMillen ◽  
Sejal Morjaria ◽  
N. Esther Babady
Keyword(s):  
Cancer Patient ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Medical Records ◽  
Patient Population ◽  
Clinical Performance ◽  
Lateral Flow ◽  
Lateral Flow Assay ◽  
Wide Range ◽  
Galactomannan Antigen

Background: The diagnosis of invasive aspergillosis can be challenging in cancer patients. Herein, the analytical and clinical performance of the sōna Aspergillus Galactomannan Lateral Flow Assay (GM LFA) was evaluated and its performance compared to that of the Bio-Rad Galactomannan EIA (GM EIA). Materials/methods: Serum and Bronchoalveolar lavage (BAL) fluids received for GM EIA testing between March-August 2019 were included. Positive and negative percent agreement (PPA and NPA) were calculated for the GM LFA compared to the GM EIA. Discrepant analysis was performed by review of the patient‘s medical records assessing for any evidence of a fungal infection. Results: 533 samples (85 BALs and 448 serums) from 379 patients were included in the study. The overall PPA and NPA were 100% (95% CI: 72.2-100%) and 97.5% (95% CI: 95.5-98.4%) respectively. 14/24 samples were positive by LFA only. The sensitivity of the GM LFA for proven and probable IA was 100% (95% CI: 51.0-100%) and 87.5% (95% CI: 55.9-99.4%) with a specificity of 95.5% (95% CI: 92.3-97.2%) and 96.2% (95% CI: 93.4-97.7%) respectively. The sensitivity of the GM EIA for proven and probable IA was 25% (95% CI: 1.28-69.9%) and 62.5% (95% CI: 30.6-86.3%) with a specificity of 98.2% (95% CI: 96.2-99.1%) and 99.2% (95% CI: 97.7-99.8%) respectively. Conclusions: The Aspergillus GM LFA outperformed the Aspergillus GM EIA for the detection of the galactomannan antigen in our patient population. The simplicity and rapid time to results makes the Aspergillus GM LFA easy to implement in a wide range of laboratory settings.

Sign in / Sign up

Export Citation Format

Share Document